The innovative medicine leader in the field of immune-related diseases. The team members have internationalized background and they have introduced over 30 overseas products to China in their own field. It leads the global R&D of over 20 new medicines and gains NDA in 28 countries, 6 IND of innovative products in China and America. The company has wholly-owned subsidiaries in Shanghai, Hangzhou and Beijing. Other product pipelines include the first or best candidate medicine of the same kind. There will be several global registered clinical trials for multiple indications for IMG-020.
Location: United States, California, San Diego
Total raised: $21M
Investors 2
| Date | Name | Website |
| - | triwise | en.triwise... |
| - | Panacea Ve... | panaceaven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.09.2020 | Series B | $21M | - |
Mentions in press and media 22
| Date | Title | Description |
| 02.02.2024 | Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED | Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor I... |
| 13.10.2023 | Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata | IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD) An i... |
| 21.09.2023 | Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function | SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced its partnersh... |
| 05.09.2023 | David Topper Joined Inmagene as CFO | SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announ... |
| 28.04.2023 | IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study | SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants. IMG-004 is a potent,... |
| 20.03.2023 | Izokibep Phase 2b/3 Hidradenitis Suppurative Data Presented at the 2023 American Academy of Dermatology Annual Meeting | At 12 weeks, participants achieved high orders of HiSCR responses (HiSCR75 and above), including 33% achieving HiSCR100. Safety results were consistent with previous trials of izokibep and the IL-17Ai class, with no increased risk of infect... |
| 06.02.2023 | Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb | SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announced that the U.S. Food and Drug Administration (FDA) recently granted the initial investigational new drug (IND) applicati... |
| 09.08.2022 | Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 | SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participan... |
| 09.08.2022 | Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004 | SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene Biopharmaceutical ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based... |
| 06.07.2022 | Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 | SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, ba... |
Show more